Wockhardt gets US nod for anti-ulcer syrup
MUMBAI, Feb 26 (Reuters) - Drug maker Wockhardt Ltd (WCKH.BO: Quote, Profile, Research) said on Thursday it has secured U.S. Food and Drug Administration approval to sell an alcohol-free syrup of ranitidine hydrochloride, used to treat ulcers and hyper-acidity.
Ranitidine is the generic version of GlaxoSmithKline's (GSK.L: Quote, Profile, Research) Zantac, the company said in a statement.
The U.S. market for the syrup is worth $51 million, the release said.
Wockhardt also said it has secured tentative approval for an alcholol-containing formulation of ranitidine. (Reporting by Bharghavi Nagaraju; editing by Rohini Ananthan)
© Thomson Reuters 2010 All rights reserved
Economy seen growing at 7.2 pct in FY10 - govt
The forecast reinforces the possibility that the government may start to unwind its fiscal stimulus in the budget. Full Article
AIDING GREECE
Eurozone agree in principle to aid Greece - source
Euro zone countries decide to help debt-stricken Greece. Full Article | Video




India
US
UK






